Downstream process: toward cost/energy effectiveness

2022 ◽  
pp. 249-260
Author(s):  
Ramesh Kumar ◽  
Rashmi Dhurandhar ◽  
Sankha Chakrabortty ◽  
Alak Kumar Ghosh
2019 ◽  
Vol 21 (14) ◽  
pp. 3816-3826 ◽  
Author(s):  
Filipa A. Vicente ◽  
Inês S. Cardoso ◽  
Margarida Martins ◽  
Cátia V. M. Gonçalves ◽  
Ana C. R. V. Dias ◽  
...  

Besides the good performance, the downstream process based in thermo-responsive systems was shown to be efficient and of lower environmental impact.


Processes ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 874
Author(s):  
Stefan Kittler ◽  
Mihail Besleaga ◽  
Julian Ebner ◽  
Oliver Spadiut

In the past 30 years, highly specific drugs, known as antibodies, have conquered the biopharmaceutical market. In addition to monoclonal antibodies (mAbs), antibody fragments are successfully applied. However, recombinant production faces challenges. Process analytical tools for monitoring and controlling production processes are scarce and time-intensive. In the downstream process (DSP), affinity ligands are established as the primary and most important step, while the application of other methods is challenging. The use of these affinity ligands as monitoring tools would enable a platform technology to monitor process steps in the USP and DSP. In this review, we highlight the current applications of affinity ligands (proteins A, G, and L) and discuss further applications as process analytical tools.


2006 ◽  
Vol 45 (12) ◽  
pp. 4200-4207 ◽  
Author(s):  
Jiahong Liu ◽  
L. T. Fan ◽  
Paul Seib ◽  
Ferenc Friedler ◽  
Botond Bertok

2021 ◽  
pp. 126609
Author(s):  
Chuang Chen ◽  
Xuemeng Zhang ◽  
Chao Liu ◽  
Yang Wu ◽  
Guanghong Zheng ◽  
...  

2005 ◽  
Vol 52 (3) ◽  
pp. 703-711 ◽  
Author(s):  
Jochen Urthaler ◽  
Wolfgang Buchinger ◽  
Roman Necina

Gene therapy and genetic vaccines promise to revolutionize the treatment of inherited and acquired diseases. Since viral vectors are generally associated with numerous disadvantages when applied to humans, the administration of naked DNA, or DNA packed into lipo- or polyplexes emerge as viable alternatives. To satisfy the increasing demand for pharmaceutical grade plasmids we developed a novel economic downstream process which overcomes the bottlenecks of common lab-scale techniques and meets all regulatory requirements. After cell lysis by an in-house developed gentle, automated continuous system the sequence of hydrophobic interaction, anion exchange and size exclusion chromatography guarantees the separation of impurities as well as undesired plasmid isoforms. After the consecutive chromatography steps, adjustment of concentration and final filtration are carried out. The final process was proven to be generally applicable and can be used from early clinical phases to market-supply. It is scaleable and free of animal-derived substances, detergents (except lysis) and organic solvents. The process delivers high-purity plasmid DNA of homogeneities up to 98% supercoiled form at a high yield in any desired final buffer.


Diagnostyka ◽  
2019 ◽  
Vol 20 (4) ◽  
pp. 57-64 ◽  
Author(s):  
Volodymyr Malashchenko ◽  
Oleh Strilets ◽  
Volodymyr Strilets ◽  
Sylwester Kłysz
Keyword(s):  

2022 ◽  
pp. 462806
Author(s):  
Julia Scheffel ◽  
Madelène Isaksson ◽  
Joaquín Gomis-Fons ◽  
Hubert Schwarz ◽  
Niklas Andersson ◽  
...  

2014 ◽  
Vol 960 ◽  
pp. 34-42 ◽  
Author(s):  
Elisa Gecchele ◽  
Stefan Schillberg ◽  
Matilde Merlin ◽  
Mario Pezzotti ◽  
Linda Avesani

Sign in / Sign up

Export Citation Format

Share Document